• Log in with Facebook Log in with Twitter Log In with Google      Sign In    
  • Create Account
  LongeCity
              Advocacy & Research for Unlimited Lifespans
  • .org
  • Districts
  • Media
  • SupportUs
  • Collaborate
  • Contact
  • Search
  • Join


Adverts help to support the work of this non-profit organisation. To go ad-free join as a Member.


Photo

BioTime Inc.

Started by caliban , Mar 25 2011 01:11 AM
economics regenerative medicine stemells tissue engineering regmed

  • Please log in to reply
777 replies to this topic

#391 ImmInst

  • Admin, Director robot
  • 2,357 posts
  • 73 ₮

Posted 13 January 2014 - 02:03 PM

BioTime Reports Results of Clinical Safety Trial of Renevia™
Wall Street Journal - 12 hours ago
BioTime, Inc. (NYSE MKT: BTX) today announced the completion of a safety trial evaluating Renevia™, a proprietary injectable matrix designed to facilitate the stable engraftment of transplanted cells, and the results of that study.

View the full article

#392 ImmInst

  • Admin, Director robot
  • 2,357 posts
  • 73 ₮

Posted 17 January 2014 - 01:52 PM

BioTime's Subsidiary LifeMap Sciences Announces Release of LifeMap ...
SYS-CON Media (press release) - 3 hours ago
LifeMap Sciences, Inc., a subsidiary of BioTime, Inc. (NYSE MKT: BTX), announced today the release of LifeMap Discoveryâ„¢ version 1.5 (discovery.

View the full article

#393 ImmInst

  • Admin, Director robot
  • 2,357 posts
  • 73 ₮

Posted 17 January 2014 - 01:52 PM

BioTime's Subsidiary LifeMap Sciences Announces Release of LifeMap ...
Business Wire (press release) - Jan 17, 2014
ALAMEDA, Calif.--(BUSINESS WIRE)--LifeMap Sciences, Inc., a subsidiary of BioTime, Inc. (NYSE MKT: BTX), announced today the release of LifeMap Discoveryâ„¢ version 1.5 (discovery.

View the full article

sponsored ad

  • Advert

#394 ImmInst

  • Admin, Director robot
  • 2,357 posts
  • 73 ₮

Posted 17 January 2014 - 01:52 PM

BioTime subsidiary releases version 1.5 of LifeMap Discovery
News-Medical.net - Jan 17, 2014
LifeMap Sciences, Inc., a subsidiary of BioTime, Inc. (NYSE MKT: BTX), announced today the release of LifeMap Discoveryâ„¢ version 1.5 (discovery.

View the full article

#395 ImmInst

  • Admin, Director robot
  • 2,357 posts
  • 73 ₮

Posted 21 January 2014 - 02:26 PM

Watch List – Facebook Inc (NASDAQ:FB), BioTime, Inc. (NYSEMKT:BTX ...
Property Mentor - 1 hour ago
iStrategyLabs has published some research that indicates a 25% decline in teen usage of Facebook Inc (NASDAQ:FB) over the past three years.

View the full article

#396 ImmInst

  • Admin, Director robot
  • 2,357 posts
  • 73 ₮

Posted 27 January 2014 - 02:03 PM

BioTime, Inc. Subsidiary OncoCyte Corporation Initiates Clinical Development ...
Wall Street Journal - 5 hours ago
BioTime, Inc. (NYSE MKT: BTX) and its subsidiary OncoCyte Corporation today announced that OncoCyte has initiated clinical development of its bladder cancer diagnostic test in both the United States and China.

View the full article

#397 ImmInst

  • Admin, Director robot
  • 2,357 posts
  • 73 ₮

Posted 27 January 2014 - 02:15 PM

BioTime (BTX) Unit Starts Bladder Cancer Diagnostic Test in US, China
StreetInsider.com (subscription) - 19 hours ago
BioTime, Inc. (AMEX: BTX) and its subsidiary OncoCyte Corporation announced that OncoCyte has initiated clinical development of its bladder cancer diagnostic test in both the United States and China.

View the full article

#398 ImmInst

  • Admin, Director robot
  • 2,357 posts
  • 73 ₮

Posted 29 January 2014 - 08:37 AM

OncoCyte starts clinical development of bladder cancer diagnostics test in US ...
pharmabiz.com - 1 hour ago
BioTime, Inc., a biotechnology company, announced that its subsidiary OncoCyte Corporation has initiated clinical development of its bladder cancer diagnostic test in both the United States and China.

View the full article

#399 ImmInst

  • Admin, Director robot
  • 2,357 posts
  • 73 ₮

Posted 29 January 2014 - 08:37 AM

OncoCyte starts clinical development of bladder cancer diagnostics test in US ...
pharmabiz.com - Jan 29, 2014
BioTime, Inc., a biotechnology company, announced that its subsidiary OncoCyte Corporation has initiated clinical development of its bladder cancer diagnostic test in both the United States and China.

View the full article

#400 ImmInst

  • Admin, Director robot
  • 2,357 posts
  • 73 ₮

Posted 29 January 2014 - 08:42 AM

OncoCyte starts clinical development of bladder cancer diagnostics test in US ...
pharmabiz.com - Jan 29, 2014
BioTime, Inc., a biotechnology company, announced that its subsidiary OncoCyte Corporation has initiated clinical development of its bladder cancer diagnostic test in both the United States and China.

View the full article

#401 ImmInst

  • Admin, Director robot
  • 2,357 posts
  • 73 ₮

Posted 18 February 2014 - 01:41 PM

BioTime CEO Dr. Michael West to Present at 9(th) Annual Stem Cell Summit
Wall Street Journal - 2 hours ago
BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D. West, PhD will present at the 9(th) Annual Stem Cell Summit in New ...

View the full article

#402 ImmInst

  • Admin, Director robot
  • 2,357 posts
  • 73 ₮

Posted 27 February 2014 - 11:37 PM

Insider Buying: Broadwood Partners Lp Buys 500000 Shares of BioTime Stock ...
Zolmax - 2 hours ago
BioTime Inc. logo BioTime (NYSE:BTX) Director Broadwood Partners Lp acquired 500,000 shares of the stock on the open market in a transaction that occurred on Tuesday, February 25th.

View the full article

#403 ImmInst

  • Admin, Director robot
  • 2,357 posts
  • 73 ₮

Posted 01 March 2014 - 12:56 AM

Investor takes his cue from insider-trading signals
The Globe and Mail - 2 hours ago
Half in basic materials stocks (includes Allana Potash Corp., Brigus Gold Corp. and Thompson Creek Metals Co. Inc.), the other half in stocks with significant insider trading (currently includes Navidea Biopharmaceuticals Inc., Amarin Corp.

View the full article

#404 ImmInst

  • Admin, Director robot
  • 2,357 posts
  • 73 ₮

Posted 03 March 2014 - 02:03 PM

BioTime Provides Financing and Product Development Update
Wall Street Journal - Mar 3, 2014
BioTime, Inc. (NYSE MKT: BTX) today announced the results of its capital raising activities since October 1, 2013 through its $25 million Controlled Equity Offering facility, and through sales of BioTime common shares by certain of its subsidiaries, ...

View the full article

#405 ImmInst

  • Admin, Director robot
  • 2,357 posts
  • 73 ₮

Posted 06 March 2014 - 05:03 PM

Panelists Announced for Second Annual Regen Med and Advanced Therapies ...
SmallCap Network - 1 hour ago
Aastrom Biosciences, ACT, Athersys, Biomatrica, BioTime, bluebird bio, BrainStorm Cell Therapeutics, Capricor, Cardio3 Biosciences, Cellular Dynamics International, Cesca Therapeutics, Cytori Therapeutics, Fate Therapeutics, Fibrocell Science, Harvard ...

View the full article

#406 ImmInst

  • Admin, Director robot
  • 2,357 posts
  • 73 ₮

Posted 17 March 2014 - 10:52 PM

BioTime Inc.: BioTime Announces Fourth Quarter and Fiscal Year End 2013 ...
The Wall Street Transcript - 1 hour ago
17, 2014-- BioTime, Inc. (NYSE MKT: BTX), today reported financial results for the fourth quarter and year ended December 31, 2013 and highlighted its fourth quarter and recent corporate accomplishments.

View the full article

#407 ImmInst

  • Admin, Director robot
  • 2,357 posts
  • 73 ₮

Posted 25 March 2014 - 12:56 PM

BioTime To Present at Regen Med Investor Day March 26 in New York
Business Wire (press release) - Mar 25, 2014
ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D. West, PhD will present at the ...

View the full article

#408 ImmInst

  • Admin, Director robot
  • 2,357 posts
  • 73 ₮

Posted 01 April 2014 - 12:56 PM

Wall Street Fundamentals Releases New In-Depth Stock Reports on BTX, CORT ...
Baystreet.ca - 1 hour ago
BioTime, Inc. (NYSEMKT: BTX) shares traded in the range of $3.01 to $3.29 Monday before settling to close at $3.29, an increase of 5.79 percent.

View the full article

#409 ImmInst

  • Admin, Director robot
  • 2,357 posts
  • 73 ₮

Posted 08 April 2014 - 12:56 AM

BioTime to Present at 13th Annual Needham Healthcare Conference
PharmiWeb.com (press release) - Apr 8, 2014
BioTime Inc. (NYSE MKT: BTX) a biotechnology company that develops and markets products in the field of regenerative medicine today announced that Chief Executive Officer Michael D. West PhD will present at the 13th Annual Needham Healthcare ...

View the full article

#410 ImmInst

  • Admin, Director robot
  • 2,357 posts
  • 73 ₮

Posted 08 April 2014 - 04:48 PM

BioTime To Present At Needham Healthcare Conference; Presentation At 1:40 ...
NASDAQ - Apr 8, 2014
(RTTNews.com) - BioTime Inc. ( BTX ) will present at the 13th Annual Needham Healthcare Conference in New York City. The event is scheduled to begin at 1:40 PM ET on April 8, 2014.

View the full article

#411 ImmInst

  • Admin, Director robot
  • 2,357 posts
  • 73 ₮

Posted 14 April 2014 - 01:05 PM

BioTime, Inc. Announces Board Membership Changes and Management and ...
MarketWatch - 1 hour ago
ALAMEDA, Calif., Apr 14, 2014 (BUSINESS WIRE) -- BioTime, Inc. (nyse mkt:BTX) announced that its Board of Directors has appointed Deborah Andrews and David Schlachet to the Board of Directors.

View the full article

#412 ImmInst

  • Admin, Director robot
  • 2,357 posts
  • 73 ₮

Posted 14 April 2014 - 12:56 PM

BioTime, Inc. Announces Board Membership Changes and Management and ...
Business Wire (press release) - Apr 14, 2014
BUSINESS WIRE)--BioTime, Inc. (NYSE MKT: BTX) announced that its Board of Directors has appointed Deborah Andrews and David Schlachet to the Board of Directors.

View the full article

#413 ImmInst

  • Admin, Director robot
  • 2,357 posts
  • 73 ₮

Posted 14 April 2014 - 12:56 PM

BioTime, Inc. Announces Board Membership Changes and Management and ...
MarketWatch - Apr 14, 2014
ALAMEDA, Calif., Apr 14, 2014 (BUSINESS WIRE) -- BioTime, Inc. (nyse mkt:BTX) announced that its Board of Directors has appointed Deborah Andrews and David Schlachet to the Board of Directors.

View the full article

#414 ImmInst

  • Admin, Director robot
  • 2,357 posts
  • 73 ₮

Posted 24 April 2014 - 12:56 PM

BioTime to Present at GTC Stem Cell Summit 2014
FierceBiotech - 3 hours ago
BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D. West, PhD will present at the taking place April 23-25, 2014 in ...

View the full article

#415 ImmInst

  • Admin, Director robot
  • 2,357 posts
  • 73 ₮

Posted 01 May 2014 - 01:18 PM

BioTime Division ESI BIO Launches New Responsive Design Website to the ...
Business Wire (press release) - 3 hours ago
BUSINESS WIRE)--BioTime, Inc. through its new research products division ESI BIO, today unveiled a new responsive design website, www.

View the full article

#416 ImmInst

  • Admin, Director robot
  • 2,357 posts
  • 73 ₮

Posted 05 May 2014 - 12:56 PM

BioTime Raises $6.4 Million in Equity Financing
PharmiWeb.com (press release) - 2 hours ago
BioTime Inc. (NYSE MKT: BTX) a biotechnology company that develops and markets products in the field of regenerative medicine today announced that on May 1 2014 the Company received approximately $6.4 million in equity financing.
BioTime Director Broadwood Partners Lp Acquires 2000000 Shares (BTX) - WKRB News

View the full article

#417 ImmInst

  • Admin, Director robot
  • 2,357 posts
  • 73 ₮

Posted 05 May 2014 - 01:18 PM

BioTime Director Broadwood Partners Lp Acquires 2000000 Shares (BTX)
WKRB News - 8 hours ago
BioTime Inc. logo BioTime (NYSE:BTX) Director Broadwood Partners Lp acquired 2,000,000 shares of BioTime stock on the open market in a transaction dated Thursday, May 1st.

View the full article

#418 ImmInst

  • Admin, Director robot
  • 2,357 posts
  • 73 ₮

Posted 07 May 2014 - 12:09 PM

Biotime spinoff LifeMap Solutions raises $5 million in seed funding
San Francisco Business Times (blog) - 33 minutes ago
LifeMap Solutions Inc., a mobile health spinoff by Alameda's BioTime Inc., has nabbed $5 million in initial funding. The funding came from LifeMap Sciences Inc., another BioTime subsidiary, with "in-kind support" from the Icahn School of Medicine at ...
LifeMap Solutions, Inc. to Develop Mobile Health Products With Mount Sinai's ... - MarketWatch
LifeMap Solutions Emerges to Develop Big Data-Powered Mobile Health Products - TriplePoint Newsroom (press release)

View the full article

#419 ImmInst

  • Admin, Director robot
  • 2,357 posts
  • 73 ₮

Posted 09 May 2014 - 12:00 PM

Broadwood Capital Acquires 2 Mln Shares of BioTime, Inc. (BTX)
Tech Insider - 1 hour ago
Neal C. Bradsher's Broadwood Capital has raised its stake in BioTime, Inc. (NYSEMKT:BTX), a recent Form 4 filing with the Securities and Exchange Commission shows.

View the full article

#420 ImmInst

  • Admin, Director robot
  • 2,357 posts
  • 73 ₮

Posted 10 May 2014 - 01:23 AM

BioTime Director Buys $732000 in Stock (BTX)
WKRB News - 2 hours ago
BioTime Inc. logo BioTime (NYSE:BTX) Director Broadwood Partners Lp acquired 300,000 shares of the company's stock in a transaction that occurred on Thursday, May 8th.

View the full article
Back to Ventures & Markets



Also tagged with one or more of these keywords: economics, regenerative medicine, stemells, tissue engineering, regmed

9 user(s) are reading this topic

0 members, 9 guests, 0 anonymous users

  1. LONGECITY
  2. → Round Table Discussion
  3. → Business
  4. → Ventures & Markets
  5. site rules